A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

被引：3
|
作者：
Oh, D-Y. [1 ]
de Braud, F. [2 ]
Bridgewater, J. [3 ]
Furuse, J. [4 ]
Hsu, C-H. [5 ]
Ikeda, M. [6 ]
Javle, M. [7 ]
Moehler, M. [8 ]
Park, J. O. [9 ]
Shen, L. [10 ]
Yoo, C. [11 ]
Helwig, C. [12 ]
Osada, M. [13 ]
Borad, M. [14 ]
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea
[2] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] UCL, Res Dept Oncol, Inst Canc, London, England
[4] Kyorin Univ, Dept Med Oncol, Sch Med, Tokyo, Tokyo, Japan
[5] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan
[6] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan
[7] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX 77030 USA
[8] Mainz Univ Hosp, Dept Gastroenterol, Hepatol, Mainz, Germany
[9] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[10] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China
[11] Univ Ulsan, Med Ctr, Coll Med, Seoul, South Korea
[12] Merck KGaA, Biostat, Darmstadt, Germany
[13] Merck Biopharma, Biostat, Tokyo, Japan
[14] Mayo Clin, Ctr Canc, Oncol, Scottsdale, AZ USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
79TiP
引用
收藏
页码：S271 / S272
页数：2
相关论文
共 50 条
  • [1] Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer
    Oh, Do-Youn
    de Braud, Filippo
    Bridgewater, John
    Furuse, Junji
    Hsu, Chih-Hung
    Ikeda, Masafumi
    Lee, Sunyoung
    Moehler, Markus
    Park, Joon Oh
    Shen, Lin
    Yoo, Changhoon
    Helwig, Christoph
    Osada, Motonobu
    Borad, Mitesh
    ANNALS OF ONCOLOGY, 2021, 32 : S333 - S333
  • [2] Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial
    Oh, Do-Youn
    Ikeda, Masafumi
    Lee, Choong-kun
    Rojas, Carlos
    Hsu, Chih-Hung
    Kim, Jin Won
    Shen, Lin
    Furuse, Junji
    Park, Joon Oh
    Borad, Mitesh
    de Braud, Filippo
    Bridgewater, John
    Lee, Sunyoung S.
    Moehler, Markus
    Audhuy, Francois
    Osada, Motonobu
    Sato, Masashi
    Yoo, Changhoon
    HEPATOLOGY, 2025, 81 (03) : 823 - 836
  • [3] Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.
    Sama, Ashwin Reddy
    Denlinger, Crystal Shereen
    Vogel, Arndt
    He, Aiwu Ruth
    Bousmans, Nathalie
    Zhang, Wei
    Walgren, Richard A.
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
    Knox, J.
    McNamara, M. G.
    Goyal, L.
    Cosgrove, D.
    Springfeld, C.
    Sjoquist, K.
    Park, J. O.
    Verdaguer, H.
    Braconi, C.
    Ross, P.
    Oh, D-Y.
    De Gramont, A.
    Shroff, R. T.
    Zalcberg, J. R.
    Palmer, D.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2021, 32 : S381 - S381
  • [5] Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
    Knox, J.
    Bazin, I.
    Oh, D.
    Zubkov, O.
    Breder, V.
    Bai, L.
    Christie, A.
    McNamara, M.
    Goyal, L.
    Cosgrove, D.
    Springfeld, C.
    Sjoquist, K.
    Park, J.
    Verdaguer, H.
    Braconi, C.
    Ross, P.
    de Gramont, A.
    Shroff, R.
    Zalcberg, J.
    Palmer, D.
    Valle, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S180 - S181
  • [6] Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
    Knox, Jennifer J.
    McNamara, Mairead Geraldine
    Goyal, Lipika
    Cosgrove, David
    Springfeld, Christoph
    Sjoquist, Katrin Marie
    Park, Joon Oh
    Verdaguer, Helena
    Braconi, Chiara
    Ross, Paul J.
    De Gramont, Aimery
    Shroff, Rachna T.
    Zalcberg, John Raymond
    Palmer, Daniel H.
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [7] Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma
    Thongprasert, S
    Napapan, S
    Charoentum, C
    Moonprakan, S
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 279 - 281
  • [8] Phase III study of NUC-1031+cisplatin versus gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
    Knox, Jennifer J.
    McNamara, Mairead Geraldine
    Goyal, Lipika
    Cosgrove, David
    Springfeld, Christoph
    Sjoquist, Katrin Marie
    Park, Joon Oh
    Verdaguer, Helena
    Braconi, Chiara
    Ross, Paul J.
    Oh, Do-Youn
    De Gramont, Aimery
    Zalcberg, John Raymond
    Palmer, Daniel H.
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial
    Valle, J. W.
    Bousmans, N.
    Zhang, W.
    Walgren, R. A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2016, 27 : vi240
  • [10] Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
    Knox, J. J.
    McNamara, M. G.
    Goyal, L.
    Doherty, M.
    Cosgrove, D.
    Springfeld, C.
    Sjoquist, K.
    Park, J. O.
    Verdaguer, H.
    Braconi, C.
    Ross, P.
    De Gramont, A.
    Zalcberg, J. R.
    Palmer, D.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S272 - S273
12345